Autoantigen Microarray for High-throughput Autoantibody Profiling in Systemic Lupus Erythematosus  by Zhu, Honglin et al.
Genomics Proteomics Bioinformatics 13 (2015) 210–218HO ST E D  BY
Genomics Proteomics Bioinformatics
www.elsevier.com/locate/gpb
www.sciencedirect.comREVIEWAutoantigen Microarray for High-throughput
Autoantibody Profiling in Systemic Lupus
Erythematosus* Corresponding authors.
E-mail: Quan.Li@UTSouthwestern.edu (Li QZ), susanzuo@hotmail.com (Zuo X).
a ORCID: 0000-0002-9322-5684.
b ORCID: 0000-0001-5593-8563.
c ORCID: 0000-0002-9509-2336.
d ORCID: 0000-0002-3928-9660.
e ORCID: 0000-0002-7257-0489.
Peer review under responsibility of Beijing Institute of Genomics, Chinese Academy of Sciences and Genetics Society of China.
http://dx.doi.org/10.1016/j.gpb.2015.09.001
1672-0229  2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Beijing Institute of Genomics, Chinese Academy of Scie
Genetics Society of China.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Honglin Zhu 1,2,a, Hui Luo 1,2,b, Mei Yan 2,c, Xiaoxia Zuo 1,*,d, Quan-Zhen Li 2,*,e1Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha 410008, China
2Department of Immunology and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75235, USAReceived 17 August 2015; revised 21 September 2015; accepted 23 September 2015
Available online 28 September 2015
Handled by Xiangdong FangKEYWORDS
Systemic lupus erythemato-
sus (SLE);
Autoantibody profiling;
Proteomic microarray;
Biomarker;
High-throughput assayAbstract Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by
the production of autoantibodies to a broad range of self-antigens. Profiling the autoantibody
repertoire using array-based technology has emerged as a powerful tool for the identification of
biomarkers in SLE and other autoimmune diseases. Proteomic microarray has the capacity to hold
large number of self-antigens on a solid surface and serve as a high-throughput screening method
for the determination of autoantibody specificities. The autoantigen arrays carrying a wide variety
of self-antigens, such as cell nuclear components (nucleic acids and associated proteins), cytoplas-
mic proteins, phospholipid proteins, cell matrix proteins, mucosal/secreted proteins, glomeruli, and
other tissue-specific proteins, have been used for screening of autoantibody specificities associated
with different manifestations of SLE. Arrays containing synthetic peptides and molecular modified
proteins are also being utilized for identification of autoantibodies targeting to special antigenic epi-
topes. Different isotypes of autoantibodies, including IgG, IgM, IgA, and IgE, as well as other Ig
subtypes, can be detected simultaneously with multi-color labeled secondary antibodies. Serum and
plasma are the most common biologic materials for autoantibody detection, but other body fluids
such as cerebrospinal fluid, synovial fluid, and saliva can also be a source of autoantibody detection.nces and
Zhu H et al / Autoantibody Profiling in Systemic Lupus Erythematosus 211Proteomic microarray as a multiplexed high-throughput screening platform is playing an
increasingly-important role in autoantibody diagnostics. In this article, we highlight the use of
autoantigen microarrays for autoantibody exploration in SLE.Introduction
Systemic lupus erythematosus (SLE) is a prototype of chronic
autoimmune connective tissue disease with an insidious onset
that can affect almost every system and organ in the human
body, especially the musculoskeletal, renal, cardiovascular,
mucocutaneous, and central nervous systems [1–3]. SLE has
diverse manifestations accompanied by a large number of
autoantibodies. So far, more than 180 autoantibody specifici-
ties have been found in the blood of SLE patients, although
different patients may exhibit different autoantibody profiles
[4–6]. Circulating autoantibodies can be detected years prior
to the clinical onset of SLE and in some patients the number
of distinct autoantibodies was found to increase over time
[7,8]. It is conceivable that some of the autoantibodies play
pathogenic roles and are associated, at least in part, with the
wide spectrum of clinical manifestations in SLE [9,10]. Cur-
rently, the clinical diagnosis of SLE relies on the presence of
at least 4 out of the 11 criteria suggested by the American Col-
lege of Rheumatology (ACR) [1]. The presence of anti-nuclear
antibodies (ANA) in patient’s serum is the most important lab-
oratory criteria for SLE diagnosis. ANA represents a cluster of
autoantibodies targeting to various components of the cell
nucleus and is positive in over 90% of SLE patients [11]. How-
ever, about 20% of the general population can show ANA
positivity in their sera, and among them approximately 2.5%
of unaffected individuals may have very high ANA levels
[11,12]. ANA is also present in other autoimmune diseases,
such as Sjogren’s syndrome (SS), scleroderma, rheumatoid
arthritis, and mixed connective tissue disease (MCTD). Thus,
although ANA has been used as a serological marker for diag-
nosis of SLE for many years, its value has been sometimes dis-
counted due to its poor specificity [12].
Autoantigen array as a high-throughput autoantibody
screening platform has the potential to distinguish autoanti-
body specificities against a wide spectrum of autoantigens
and is therefore valuable for the evaluation of the correlation
between autoantibodies and clinical manifestations [13–16].
Previous studies have shown that autoantibodies can exist in
sera of SLE patients many years prior to the onset of clinical
disease and the number of autoantibodies correlated with dis-
ease severity [7,8]. Hence, profiling autoantibodies using high-
throughput autoantigen arrays may have important implica-
tions for early diagnosis and prognosis of SLE.
Autoantigen microarray: principle and methodology
The principle of proteome microarray was firstly described by
MacBeath and Schreiber who developed a miniaturized assay,
which had the capacity to accommodate thousands of proteins
[17]. They used a high-precision contact-printing robot to deli-
ver nanoliter volumes of protein onto chemically-derivatized
glass slides. The proteins were covalently attached to the sub-
strate coated on the slide surface, which retained their activity
to interact with other proteins, or small molecules, in solution.As a proof-of-principle test, they demonstrated three applica-
tions for protein microarrays: to screen for interactions
between proteins, to identify the substrates of protein kinases,
and to identify the small molecules as targets of the proteins
[17]. The important application of proteomic microarray is
for high-throughput quantitative detection of the interactions
between specific antigens and antibodies in complex solutions.
Haab et al. analyzed the specificity, sensitivity, and accuracy of
protein array on 115 antibody/antigen pairs. Over 50% of the
arrayed antigens were specifically detected by their corre-
sponding antibodies with the sensitivity at or below the con-
centration of 0.34 lg/ml. Moreover, some even allowed
detection of the cognate antibodies at absolute concentrations
below 1 ng/ml, which is sensitive enough for measurement of
many clinically-important proteins in patients’ blood samples
[13].
Autoantigen array is a specified proteome microarray for
large-scale detection of autoantibodies on the basis of anti-
gen–antibody reaction as shown in Figure 1. Autoantigen
can be any of an organism’s own antigens (self-antigens),
e.g., nuclear antigens, cytoplasmic antigens, cell membrane
antigens, phospholipid-associated antigens, blood cells,
endothelial cells, glomerular basement membrane, mitochon-
dria, muscle, parietal cells, thyroglobulin, nervous system anti-
gens, plasma proteins, matrix proteins, and miscellaneous
antigens, which may evoke production of autoantibodies.
The common autoantigens identified in SLE are listed in
Table 1. Among them, the nuclear antigens are the most pop-
ular autoantigens targeted by autoantibodies in SLE. The
methodology underlying the autoantigen microarray has been
reviewed previously [16,18] and is briefly described as follows.
The autoantigen arrays are produced by immobilizing hun-
dreds or even thousands of diverse autoantigens on the coated
surface of glass slides. The autoantigens can be nucleotide
(DNA or RNA) or purified proteins from tissues, in vitro-
expressed recombinant proteins, or synthetic peptides and
the glass slides can be coated with nitrocellulose membrane
(NC), hydrogel, or polymers, which hold the proteins in their
native conformation. After blocking, the arrays are hybridized
with diluted biological samples (serum, body fluids, or cell cul-
ture supernatant), and finally the autoantibodies bound to
their corresponding antigens on the array are detected with
the fluorophore-conjugated second antibodies against different
isotypes of autoantibodies (IgG/IgM/IgA/IgE). Shown in
Figure 1 is the multiplex autoantigen microarray chip, which
can process 16 samples on one chip in one run and detect
125 autoantibodies for both IgG and IgM isotypes.
There are some obvious advantages of the autoantigen
array over the conventional ANA detection methods such as
indirect immunofluorescence (IF) and ELISA [19]. Use of
the aforementioned conventional methods to analyze multiple
antibodies in multiple samples may incur substantial cost,
time, manpower, and even the serum samples. In contrast,
autoantigen arrays can be easily performed as high-
throughput assays, using smaller volume of serum (1–2 ll)
and at much lower cost. Most significantly, autoantigen array
A B C 
Figure 1 Autoantigen microarray for high-throughput autoantibody screening
A. Mechanism of autoantigen microarray. Autoantigens are immobilized onto nitrocellulose-coated slides, after hybridization with
samples, the autoantibodies bound with autoantigens are detected with fluorescent dye-labeled secondary antibodies. B. Image of
multiplex autoantigen arrays for detection of human IgG and IgM autoantibodies. Each slide has 16 identical arrays of 128 antigens.
Arrays are hybridized with human sera, detected by Cy3-labeled anti-human IgG and Cy5-labeled anti-human IgM antibodies, and
scanned with Axon 4000B scanner. C. Autoantigen microarray data analysis. Heatmap (top panel) is generated by Cluster and TreeView
software using the signal intensity of the autoantibodies to all samples. The graphs in the lower panel show the statistical analysis using
Prism 6 software.
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thousands of autoantibodies in a quantitative manner. It has
been demonstrated that data generated by autoantigen arrays
were correlated very well with the data generated by ELISA,
however with much higher sensitivity [20–22].
Autoantigen arrays for multiplex characterization
of autoantibodies
Autoantigen microarray for large-scale detection of autoanti-
body responses was first reported by Robinson and colleagues
[20]. They fabricated 1152-feature arrays containing 196 puta-
tive autoantigens, which have been reported to be targeted by
autoantibodies in different autoimmune disorders. These
included 36 recombinant or purified proteins and 154 overlap-
ping and immunodominant peptides of the autoantigens. The
autoantigen arrays, which were incubated with a mixture of
sera derived from patients with SLE, polymyositis (PM), or
primary biliary cirrhosis (PBC), specifically identified autoan-
tibodies recognizing mammalian double-stranded DNA
(dsDNA), synthetic single-stranded DNA (ssDNA), histone
H2A, U1 small nuclear ribonucleoprotein (U1-snRNP), Smith
antigen (Sm), Sm/RNP complexes, Ro52, Jo-1, and pyruvate
dehydrogenase (PDH). Moreover, the autoantigen arrays
showed a consistently 4–8-fold higher sensitivity than ELISA
for detecting antigen specific autoantibodies [20].
Using the same autoantigen arrays, this group also detected
isotype-specific mouse autoantibodies. They measured IgG1
and IgG2a antibody isotype in a murine model of autoimmu-
nity using isotype-specific secondary antibodies labeled with
Cy3 and Cy5. As a result, they demonstrated that the autoanti-
gen array can quantitatively monitor changes in isotype mAb
concentration [21]. Thus, autoantigen microarray technologyhas been shown to be a sensitive and specific assay for quanti-
tative measurement of antibody subclasses in biological sam-
ples, such as serum, cerebrospinal fluid (CSF), peritoneal
fluid, and synovial fluid [20,21].
Autoantigen arrays for profiling autoantibodies
in SLE and incomplete LE
To provide a comprehensive understanding of the autoanti-
body repertoires during the development of SLE, Li and
colleagues developed protein microarrays comprising a collec-
tion of autoantigens related to various autoimmune disorders
[22,23]. Using these antigen microarrays, they identified
autoantibody clusters associated with overall disease activity
and lupus nephritis (LN) [22]. They further analyzed the
autoantibody profiles in a subset of patients with incomplete
LE (ILE), defined as having at least one but less than four
of the SLE diagnostic criteria and in first-degree relatives
(FDR) with SLE. By comparing the serum levels of IgG and
IgM autoantibody isotypes in the subgroups of healthy con-
trols (HCs), ILE, and SLE, they found that patients in SLE
group exhibited increased level of IgG autoantibodies com-
pared with ILE, whereas alterations in IgM autoantibodies
showed the opposite trends: high in ILE but low in SLE,
implying that there might be a class switch from IgG to IgM
during the transition from ILE to SLE [23]. Furthermore, in
combination with transcriptional profiling, they found the
association between the peripheral blood interferon (IFN) sig-
nature and serum autoantibodies in patients with SLE and
ILE. High expression of IFN signature genes were significantly
correlated with high levels of IgG autoantibodies. Therefore,
IFN may play a pathogenic role in driving IgM to IgG class-
switching in SLE [24].
Table 1 Autoantigens in SLE
Category Autoantigens
Nuclear antigens Double-stranded DNA, single-stranded DNA
Nucleosome
Chromatin
Histones: total, H1, H2A, H2B, H3, H4
DNA topoisomerase I/Scl70
Centromere: centromeric protein A (CENP-A), CENP-B
Proliferating cell nuclear antigen (PCNA)
Ku (p70/80)
Mi-2
Transcriptional intermediary factor 1 gamma (TIF1/TRIM33)
Melanoma differentiation associated protein-5 (/MDA5/IFIH1)
Sp100
Double-stranded RNA, single-stranded RNA
Ro/Sjo¨gren’s syndrome type A antigen (SSA): 52kDa, 60kDa
La/ Sjo¨gren’s syndrome type B antigen (SSB)
Smith antigen (Sm): Sm/D, SmD1, SmD2, SmD3
Ribonucleoprotein: U1-snRNP A, B/B’, C, 68kDa
Nuclear exosome: PM/Scl75, PM/Scl100
Nucleolin: C23
Ribosomal phosphoprotein: P0, P1, P2
RNA polymerase I, II, III
Histidyl-tRNA synthetase/Jo-1
Threonyl-tRNA synthetase/PL-7
Alanyl-tRNA synthetase/PL-12
Signal recognition particle/SRP54
Cytoplasmic/membrane proteins Neutrophil cytoplasmic antigens: myeloperoxidase (MPO), proteinase 3
Cytochrome P450 2D6 (LKM1)
Cytochrome C
Liver cytosol antigen type 1 (LC1)
M2: target of antimitochondrial antibodies
Tissue transglutaminase (TTG)
ß2 microglobulin
Mitochondrial antigen
Nuclear membrane-associate antigens Nuclear pore glycoprotein 210
Nucleoporin 62kDa
Cell matrix proteins Collagen I, II, III, IV, V, VI
Fibrinogen, fibronectin
Phospholipid proteins ß2-glycoprotein 1/ apolipoprotein H
Cardiolipin
Glycoprotein 2
Glomeruli-specific proteins Glomerular basement membrane
Actinin, laminin
Matrigel, amyloid, elastin
Thyroid-specific proteins Thyroid peroxidase
Thyroglobulin
Circulating proteins Complement C1q, C3, C4
Prothrombin
Intrinsic factors
Zhu H et al / Autoantibody Profiling in Systemic Lupus Erythematosus 213The same group also examined the autoantibody profiles in
ANA-positive healthy population using an autoantigen array
carrying over 100 antigens. They found that healthy popula-
tion with high ANA showed significant elevation of autoanti-
bodies against antigens in skin, kidney, thyroid, or joints. The
profiling of autoantibodies in high ANA population, in combi-
nation with other clinical features, may help to identify indi-
viduals who are at higher risk of developing SLE [25,26].Autoantigen arrays for profiling autoantibodies
associated with complications in SLE
Autoantibodies associated with LN
LN is a leading cause of mortality in SLE and autoantibodies
constitute important contributors to renal damage in this
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nephrophilic autoantibodies in SLE, Li et al. constructed a
multiplexed proteome microarray bearing 35 antigens known
to be expressed in the glomerular milieu to investigate serum
autoantibodies in both human and LN mouse model [22].
They found that LN mice (B6.Sle1.lpr) exhibited high levels
of IgG and IgM antiglomerular antibodies as well as anti-
dsDNA/chromatin antibodies and variable levels of antibodies
to a-actinin, aggrecan, collagen, entactin, fibrinogen, hemo-
cyanin, heparin sulfate, laminin, myosin, proteoglycans, and
histones. The use of these glomerular proteome arrays also
revealed five distinct clusters of IgG autoreactivity and two
clusters of IgM autoreactivity in the sera of lupus patients
[22]. The two IgG autoantibody clusters, DNA/chromatin/
glomeruli and laminin/myosin/matrigel/vimentin/heparan sul-
fate, showed strong association with disease activity, whereas
the IgM autoantibodies was associated with reduced disease
activity [22]. Further investigation of autoantibody profiling
on polycongenic mice with severe LN (B6.Sle1Sle3 and B6.
Sle1Sle5) revealed that B6.Sle1Sle3 and B6.Sle1Sle5 mice
had more IgG autoantibodies of glomerular specificities than
B6.Sle1 mice, and B6.Sle1Sle3 mice also had higher levels of
IgA autoantibodies targeting dsDNA and histone, compared
to B6 mice [27]. These studies suggested that the glomerular
proteome array promises to be a powerful analytical tool for
uncovering novel autoantibody disease associations and for
distinguishing patients at high risk for end-organ disease.
Using an antigen array bearing 694 antigen specificities,
Fattal et al. investigated autoantibodies in SLE patients on
various clinical stages – SLE with acute LN, those in renal
remission, and those who had never had renal involvement
[28]. They found that SLE patients had significantly increased
IgG autoantibodies against dsDNA, ssDNA, Epstein–Barr
virus (EBV), and hyaluronic acid, compared to healthy con-
trols. Moreover, the levels of these autoantibodies are persis-
tently higher in SLE patients even after long-term clinical
remission and independent of disease activity [28]. They also
found that IgM reactivities to myeloperoxidase (MPO),
CD99, collagen III, insulin-like growth factor binding protein
1 (IGFBP1), and cardiolipin were decreased in SLE, suggesting
that the IgM autoantibodies might enhance resistance to SLE,
consistent with the findings by Li and colleagues [22].
Autoantibodies associated with neuropsychiatric SLE
Neuropsychiatric SLE (NPSLE) is an important subtype of
SLE with complicated clinical manifestations, including asep-
tic meningitis, psychosis, and seizures, but the clinical diagno-
sis of NPSLE remains challenging due to lack of specific
biomarkers [29]. Autoantibodies in the CSF of NPSLE
patients might be directly associated with the disease status.
Indeed, various autoantibodies targeting to neuronal tissue
antigens, such as glutamate receptor e2 subunit (GluRe2), gan-
glioside, glial fibrillary acidic protein, dsDNA, N-methyl-d-
aspartate (NMDA) receptors, triose phosphate isomerase,
SSA/Ro, ribosomal P protein, cardiolipin, and alpha inter-
nexin, have been identified from CSF of NPSLE patients
[30]. Unfortunately, very few of these autoantibodies are speci-
fic to NPSLE. In order to identify more specific biomarkers
associated with NPSLE, Hu et al. screened 29 CSF specimens
from 12 NPSLE, 7 non-NPSLE, and 10 control (non-SLE)patients using a human proteome array with 17,000 unique
full-length human proteins [31]. They identified 137 autoanti-
gens associated with NPSLE, including anti-proliferating cell
nuclear antigen (PCNA), anti-60S acidic ribosomal protein
P0 (RPLP0), anti-RPLP1, anti-RPLP2, and anti-Ro/SS-A.
The titers of anti-RPLP2 and anti-SS-A in CSF were signifi-
cantly correlated with those in sera, suggesting that these
autoantibodies may be potential CSF markers for NPSLE [31].
Autoantigen arrays reveal autoantibodies in pediatric
SLE
About 10%–20% of SLE patients have disease onset in child-
hood or adolescence and are treated as pediatric SLE (pSLE).
pSLE patients often initially present with more active and sev-
ere disease manifestations than adults, including higher fre-
quency of LN, which is the primary causes of morbidity and
mortality in pSLE [32,33]. In order to reveal autoantibodies
associated with proliferative LN and disease activity in pSLE,
Haddon et al. used autoantigen microarrays composed of 140
antigens to compare the serum autoantibody profiles of 45
new-onset pSLE patients, including 23 biopsy-confirmed class
III or IV proliferative nephritis and 18 without significant
renal involvement, with the autoantibody profiles of 17 healthy
controls. They found that titers of 55 autoantibodies were sig-
nificantly higher in the sera of pSLE patients than the healthy
controls. Anti-B cell-activating factor (BAFF) antibody, which
was associated with active disease status, was on the list [34].
Furthermore, titers of 13 autoantibodies were significantly
higher in pSLE patients with proliferative LN than those with-
out. These included 5 antibodies targeting dsDNA, C1q, colla-
gen IV, collagen X, and aggrecan, which are enriched in
glomeruli. They concluded that autoantigen microarray is an
ideal platform for identifying autoantibodies associated with
both pSLE and specific clinical manifestations of pSLE [34].
Autoantigen arrays distinguish antibodies in discoid
LE
Discoid LE (DLE) is a chronic dermatological disorder pre-
sents in about 20% of SLE patients, which is usually associ-
ated with milder disease activity and lower prevalence of LN
in comparison with SLE [35]. Previous studies showed that
about 21%–63% of DLE patients are ANA positive, but the
ANA titers were usually at low range (<1:160), compared to
SLE [35]. In order to gain information on autoantibody speci-
ficities in subsets of DLE and SLE patients, Chong et al. com-
pared the autoantibody profiles in SLE patients with DLE
(DLE+SLE+) or without DLE (DLESLE+), as well as
DLE subjects without SLE (DLE+SLE), using an autoanti-
gen array containing 98 autoantigens [36]. They found that
autoantibodies targeting to several nuclear antigens (e.g.,
dsDNA, dsRNA, histone H2A, histone H2B, SS-A, and
ssDNA) showed distinctively lower levels in patients with
DLE (DLE+SLE+ and DLE+SLE) than in SLE patients
without DLE (DLESLE+), implying that DLE is a pheno-
typic marker associated with mild systemic disease. The IgG
autoantibody profile in DLE+SLE subjects is similar to that
in HCs, although a few, including three autoantibodies against
nuclear antigens (Jo-1, U1-snRNP-A, and SS-A) and two
Zhu H et al / Autoantibody Profiling in Systemic Lupus Erythematosus 215against epidermal–dermal junction proteins (HSPG and a6b4
integrin), showed slightly higher levels. However, higher level
of IgM autoantibodies against ab-crystallin, lipopolysaccha-
ride, heat-shock cognate 70 (HSC70), and desmoglein-3 were
found in DLE+SLE subjects, compared to DLESLE+
and DLE+SLE+ subjects. The IgG:IgM ratios of nuclear-
specific autoantibodies progressively increased from healthy
to DLESLE+ subjects [36], implying that lower levels of
IgG autoantibodies in DLE might be associated with lower
disease severity, whereas higher IgM autoantibodies against
selected antigens in healthy and DLE+ subjects may be
nonpathogenic.
Autoantigen array for detection of cytokine-specific
antibodies in SLE
Autoantibodies targeting to cytokines, chemokines, and other
circulating immunologic factors have been described in SLE
and other autoimmune diseases [37,38], but their profiles in
SLE have not been systemically studied. Recently Utz’s group
reported an autoantigen array bearing 59 unique human serum
factors in addition to previously-described autoantigens for
parallel detection of antibodies against known autoantigens
as well as novel immunological targets [39]. By assaying the
autoantibodies in sera of SLE patients, they revealed elevated
levels of autoantibodies targeting several serum factors in SLE,
including BAFF, TGF-b1, IL-2, IL-23, TNF, and IFN-a.
Specifically, they found that anti-BAFF reactivity was posi-
tively correlated with the level of INF-signature genes, which
is a hallmark feature of severe SLE [39,40]. These observations
imply that elevated autoantibodies targeting to serum
immunological factors may be associated with more severe
inflammatory status in SLE and may serve as useful biomark-
ers for the evaluation of disease activities [39].Other applications of autoantigen arrays in SLE
studies
Perhaps not surprisingly, autoantigen arrays have been widely
used in SLE studies. Culton et al. screened patients’ sera using
autoantigen arrays bearing 67 nuclear and glomerular autoanti-
gens to investigate the autoantibody profiles in SLE patients
with high or low CD19 expressing B cells. Their data indicate
that CD19(hi) SLE patients exhibit a distinct autoantibody pro-
file characterized by high levels of antibodies to snRNPs and
low levels of anti-glomerular autoantibodies [41], suggesting
that B cells play a crucial role in the determination of the
autoantibody specificities. On the other hand, Silverman and
colleagues are interested in finding out the genetic imprint of
autoantibody repertoires in SLE using autoantigen arrays.
From the autoantibody profiles of 38 SLE patients including
14 sets of SLE twins, they found that autoantibodies to the
phospholipid neodeterminants, malondialdehyde (MDA), and
phosphorylcholine (PC) were among the most prevalent and
highly-expressed autoantibodies in SLE. The sharing of IgG
autoantibody fingerprints by monozygotic twins suggests that
lupus IgG autoantibodies can arise in predisposed individuals
in genetically-determined patterns [42]. Another important
application of autoantigen arrays in human SLE studies is to
determine the autoantibody alterations during the transitionfrom non-active to active disease status. In a study of longitudi-
nal follow-up of 22 SLE patients, Olsen and colleagues investi-
gated the variations of IgG and IgM autoantibody specificities
in these patients along with their clinical manifestation for
2.4 years. They found that IgG but not IgM autoreactivity
increased to a greater extent in the progressor group than in
the non-progressor group. Progressors had significant increases
in IgG anti-La/SSB and liver cytosol type 1 (LC1) autoantibod-
ies over the period of evaluation (P 6 0.0072). These findings
suggest that autoantibody profiles using an expanded array of
specificities can be used to predict the risk of progressive disease
in patients with lupus [43].
Autoantigen arrays have also been applied in SLE studies
using animal models. Sekine et al. used autoantigen microarray
technology to identify distinct autoantibody profiles inH-2 con-
genic MRL/lpr mice and indicated that genes encoded within
MHC region plays critical role in the production of anti-SM
and anti-snRNP autoantibodies [44]. To investigate the associ-
ation of type 1 IFN with autoantibodies in SLE, Thibault
et al. measured the autoantibody specificities in a pristine-
induced lupus in type 1 IFN receptor 2 knockout mice
(IFNAR2/) using autoantigen arrays and found that the
absence of type 1 IFN could decrease the expression of nucleic
acid-sensing Toll-like receptors and therefore, diminish the
autoantibody production [45]. Given the fact that the high
expression of IFN-genes is a signature of SLE in human, the
study in the animal model has great value for the identification
of the underlying molecular connections between the IFN genes
and autoantibodies in SLE. A20 (also known as tumor necrosis
factor, alpha-induced protein 3, TNFAIP3) is another impor-
tant factors associated with immune regulation in autoimmune
diseases. Tavares et al. used protein arrays to analyze the
autoantibodies in sera from conditionally-knockout mice and
showed that mice with A20 deficiency in B cells possessed more
germinal center B cells, autoantibodies, and increased expres-
sion of anti-apoptotic proteins such as Bcl-x, alluding to the role
of A20 in B cell survival and lupus [46]. Similar to the above
studies, Satterthwaite’s group has also used autoantigen arrays
for screening of autoreactive antibodies in genetically-modified
mousemodels (Lyn/, Btk/, Ets1/) for finemapping of
genetic interaction between Lyn, Ets1, and Btk in the control of
antibody levels. Their data defined that there exist in vivo genetic
interactions between Ets1, Lyn, and Btk, whereas disruption of
the balance of these factors will lead to loss of immune tolerance
and autoantibody production [47–49].
Antigen arrays for discovery of novel autoantibody
biomarkers in SLE
Other than detection of autoantibodies already identified in
SLE, an important application of protein microarray is to
identify novel autoantibodies associated with the pathogenesis
of the disease. Huang et al. used protein arrays containing over
5000 recombinant human proteins to profile the autoantibod-
ies in the sera of SLE patients and compared with HCs. Four
novel antigens, i.e., PBOV1, MORF4L1, CLIC2, and GSTP1,
were identified to be potential targets of autoantibodies in
SLE. They further validated by using ELISA that the positive
rate of anti-CLIC2 in SLE was 28.18% and the level of anti-
CLIC2 in SLE was positively correlated with disease activity
in terms of SLE Disease Activity Index (SLEDAI) score and
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teome arrays bearing over 9000 human full-length proteins,
Kinloch et al. screened 25 monoclonal antibody strains cloned
from activated B cells isolated from laser-captured renal
biopsy specimens of LN patients. They identified that vimentin
is a dominant autoantigen targeted in situ in LN with severe
tubulointerstitial inflammation (TII) [51].
Technological improvement of autoantigen arrays
Technologic modification has been applied to the planar array
for the purpose of increasing its sensitivity on detecting novel
targets. Kattah et al. described a two-color antibody-binding
fragment (Fab) labeling method for protein array [52]. First,
they spiked mouse antibodies into normal mouse serum, and
then they pre-incubated the spiked samples with Cy3- or
Cy5-labeled anti-mouse monovalent Fabs, respectively. After
removing free Fabs by passing over a spin column for purifica-
tion, they mixed the two samples and applied them to a protein
array. Using this method, they discovered a previously-
unreported reactivity to Ribo P0 in autoimmune mice.
Another important modification on protein array is the
improvement of coating chemistries on the array. El Khoury
et al. developed newer surface chemistries for protein arrays
so that the protein structure and biological activity can be
retained [53]. They performed these modified arrays to evalu-
ate the anti-histone autoantibodies present in SLE patients’
sera, and compared the results with those detected using
ELISA and Western blotting. Their data indicated that arrays
had a higher sensitivity than ELISA and Western blotting, and
required smaller volume of samples.Autoantigen array data analysis
No doubt autoantigen arrays as a highly-multiplex and high-
throughput assay provided much more information than tradi-
tional assays. Nonetheless, the data interpretation and cross-
study comparison is a challenging topic facing bioinformatists.
Unlike DNA microarrays, for which various analytical algo-
rithms have been established for data mining and classifica-
tion, so far there is not an applicable data mining pipeline
available for autoantigen array data analysis. One of the inher-
ent disadvantages of antigen microarrays is the existence of
batch and inter-array variations, making it difficult to compare
results obtained from different experiments and at different
locations. Quantile and global normalizations, which are used
to reduce inter-array variability in DNA microarray, are not
readily applicable to protein array data analysis, simply
because these algorithms could introduce artifacts that distort
the signals and affect the identification of real protein signals
[54]. To overcome this limitation, Sboner et al. reported a
robust linear model (RLM) to reduce technical variability in
functional protein microarrays. They incorporated a set of
control proteins into subarrays as normalization factor and
showed that RLM normalization was able to reduce both
intra- and inter-array technical variability while maintaining
biological differences [54]. Incorporation of different internal
standards, such as tagged-internal standard (TIS), could facil-
itate the normalization and thus improve the data quality [55].
Our group has incorporated purified human Ig (IgG and IgM)and anti-human Ig (anti-human IgG and anti-human IgM) as
internal controls (https://microarray.swmed.edu/products/cat-
egory/protein-array/). We found that the replicated Ig protein
spots incorporated into arrays generated consistent signals and
are suitable for normalization between arrays. Furthermore,
the signal of anti-human IgG (or IgM) antibody incorporated
into each array could be used to measure the total amount of
IgG (or IgM) in the sera (Li et al. unpublished).
Conclusion
Autoantigen microarrays provide a unique tool to profile
autoantibodies in systemic autoimmune diseases. SLE is an
extremely-heterogeneous autoimmune disorder. The immune
system creates large number of different antibodies targeting
different antigens in different patients, which are in turn asso-
ciated with different clinical manifestation. Thus, autoantigen
array as a highly-multiplex autoantibody detection platform is
extremely valuable not only in SLE studies, but also for the
potentials of clinical applications. Since autoantibodies appear
in the blood prior to clinical onset of the disease, detection of
pathogenic autoantibodies may help to identify individuals at
risk of developing SLE. Furthermore, detection of certain pat-
terns of autoantibodies may help to monitor disease activity
and to evaluate response to therapy. As more novel autoanti-
gens/autoantibodies are being discovered and their correlation
with disease development being elucidated, the use of this high-
throughput technology in clinical diagnosis will be highly
demanded. Nevertheless, there are still a lot of technical chal-
lenges for this technology. Firstly, the panel of antigens on the
arrays and the protocol for array processing should be further
standardized so that the results from different studies could be
comparable. Secondly, since the variations between different
batch of slides or even inter-array variability are still a big con-
cern for the application of autoantigen arrays, an optimized
data normalization algorithm is in great need. To overcome
these technical limitations, the laboratory scientists are work-
ing closely with rheumatologists and bioinformatists to
improve the array design and data processing algorithms. With
the rapid application of multi-omics technologies on the bio-
marker analysis of diseases, we are anticipating that autoanti-
gen microarrays, as a high-throughput biomarker discovery
tool, should have the potential to revolutionize the diagnosis,
monitoring, and therapy of SLE.
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